Callender, T., Emberton, M., Morris, S., Eeles, R., Kote-Jarai, Z., Pharoah, P. D. P., & Pashayan, N. (2019). Polygenic risk-tailored screening for prostate cancer: A benefit–harm and cost-effectiveness modelling study. PLoS medicine, 16(12), e1002998. https://doi.org/10.1371/journal.pmed.1002998
Citácia podle Chicago (17th ed.)Callender, Tom, Mark Emberton, Steve Morris, Ros Eeles, Zsofia Kote-Jarai, Paul D. P. Pharoah, a Nora Pashayan. "Polygenic Risk-tailored Screening for Prostate Cancer: A Benefit–harm and Cost-effectiveness Modelling Study." PLoS Medicine 16, no. 12 (2019): e1002998. https://doi.org/10.1371/journal.pmed.1002998.
Citácia podľa MLA (8th ed.)Callender, Tom, et al. "Polygenic Risk-tailored Screening for Prostate Cancer: A Benefit–harm and Cost-effectiveness Modelling Study." PLoS Medicine, vol. 16, no. 12, 2019, p. e1002998, https://doi.org/10.1371/journal.pmed.1002998.